PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant’s Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific genomic alterations to provide one of the most advanced and actionable views of MRD. Validat